Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Envoy Medical (COCH) Research & Development (2022 - 2026)

Envoy Medical's Research & Development history spans 5 years, with the latest figure at $3.6 million for Q1 2026.

  • On a quarterly basis, Research & Development rose 32.53% to $3.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $13.4 million, a 26.62% increase, with the full-year FY2025 number at $12.5 million, up 22.66% from a year prior.
  • Research & Development hit $3.6 million in Q1 2026 for Envoy Medical, down from $4.6 million in the prior quarter.
  • Over the last five years, Research & Development for COCH hit a ceiling of $4.6 million in Q4 2025 and a floor of $935000.0 in Q3 2022.
  • Historically, Research & Development has averaged $2.5 million across 5 years, with a median of $2.5 million in 2025.
  • Biggest five-year swings in Research & Development: soared 111.71% in 2023 and later fell 19.12% in 2024.
  • Tracing COCH's Research & Development over 5 years: stood at $1.4 million in 2022, then surged by 111.71% to $3.1 million in 2023, then fell by 19.12% to $2.5 million in 2024, then surged by 84.26% to $4.6 million in 2025, then fell by 20.01% to $3.6 million in 2026.
  • Business Quant data shows Research & Development for COCH at $3.6 million in Q1 2026, $4.6 million in Q4 2025, and $2.7 million in Q3 2025.